14393 Real world experience using cyclosporine in psoriasis: Efficacy and toxicity in the Australasian Psoriasis Registry

Background: Cyclosporine is a calcineurin inhibitor that is approved for short-term use to treat moderate to severe chronic plaque psoriasis. In Australia it is a requirement to have trialed and failed, or have a valid contraindication to, at least two of cyclosporine, methotrexate, acitretin, or nbUVB therapy to be eligible for subsidised biologic therapy for chronic plaque psoriasis in adults. Therefore, it is important in clinical practice throughout Australia that cyclosporine efficacy and safety is well understood.

Source: Journal of the American Academy of Dermatology - November 28, 2020 Category: Dermatology Authors: William Berry, Benjamin Daniel, Peter Foley Source Type: research